Zevra Therapeutics, Inc. (ZVRA)
11.65
-0.22
(-1.85%)
USD |
NASDAQ |
Aug 24, 16:00
11.66
+0.01
(+0.09%)
After-Hours: 20:00
Zevra Therapeutics Enterprise Value : 471.26M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 471.26M |
| August 21, 2026 | 484.31M |
| August 20, 2026 | 485.50M |
| August 19, 2026 | 499.74M |
| August 18, 2026 | 466.51M |
| August 17, 2026 | 464.14M |
| August 14, 2026 | 451.68M |
| August 13, 2026 | 443.37M |
| August 12, 2026 | 458.80M |
| August 11, 2026 | 452.86M |
| August 10, 2026 | 461.17M |
| August 07, 2026 | 465.92M |
| August 06, 2026 | 484.91M |
| August 05, 2026 | 404.80M |
| August 04, 2026 | 404.20M |
| August 03, 2026 | 376.61M |
| July 31, 2026 | 344.27M |
| July 30, 2026 | 351.98M |
| July 29, 2026 | 360.29M |
| July 28, 2026 | 357.32M |
| July 27, 2026 | 356.14M |
| July 24, 2026 | 345.16M |
| July 23, 2026 | 522.89M |
| July 22, 2026 | 500.34M |
| July 21, 2026 | 518.73M |
| Date | Value |
|---|---|
| July 20, 2026 | 493.81M |
| July 17, 2026 | 537.72M |
| July 16, 2026 | 537.13M |
| July 15, 2026 | 549.00M |
| July 14, 2026 | 554.93M |
| July 13, 2026 | 562.05M |
| July 10, 2026 | 572.14M |
| July 09, 2026 | 607.15M |
| July 08, 2026 | 655.22M |
| July 07, 2026 | 636.82M |
| July 06, 2026 | 608.93M |
| July 02, 2026 | 609.53M |
| July 01, 2026 | 599.44M |
| June 30, 2026 | 630.89M |
| June 29, 2026 | 628.73M |
| June 26, 2026 | 599.76M |
| June 25, 2026 | 582.62M |
| June 24, 2026 | 573.75M |
| June 23, 2026 | 569.02M |
| June 22, 2026 | 548.33M |
| June 18, 2026 | 563.11M |
| June 17, 2026 | 545.97M |
| June 16, 2026 | 548.33M |
| June 15, 2026 | 542.42M |
| June 12, 2026 | 548.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Innoviva, Inc. | 1.218B |
| Collegium Pharmaceutical, Inc. | 1.957B |
| Johnson & Johnson | 685.82B |
| Ligand Pharmaceuticals, Inc. | 5.355B |
| Harrow, Inc. | 1.708B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 8.393M |
| Revenue (Quarterly) | 39.66M |
| Total Expenses (Quarterly) | 31.27M |
| EPS Diluted (Quarterly) | 0.1368 |
| Gross Profit Margin (Quarterly) | 95.36% |
| Profit Margin (Quarterly) | 21.16% |
| Earnings Yield | 7.96% |
| Operating Earnings Yield | 5.65% |
| Normalized Earnings Yield | 9.737 |